A Clinical Trial to Evaluate the Effects of a Supplement on Cognitive Function and Energy Levels

This study evaluates the effects of Artah's Cellular Hydration electrolyte supplement on cognitive function and energy levels in healthy adults aged 25-60 who experience mild to moderate fatigue, brain fog, or related symptoms. The trial is a single-arm, unblinded, virtual study in which all 50 participants will use the test product daily for 4 weeks. Participants will complete self-reported questionnaires at Baseline, Week 1, Week 2, Week 3, and Week 4, and will undergo cognitive battery testing at Baseline and Week 4. The primary endpoint is change in cognitive performance scores as measured by a standardized cognitive battery. Secondary endpoints include participants' self-reported perceptions of mental clarity, alertness, mood, physical performance, overall energy levels, and frequency of food cravings.

Inclusion Criteria: * Be male or female. * Be aged 25-60. * Anyone currently experiencing mild to moderate issues with at least three of the following: low energy or fatigue * difficulty concentrating or low mental sharpness * experiences of brain fog or lack of mental clarity * feeling of low productivity * muscle weakness * unwanted food cravings. * Undertakes moderate to high-intensity exercise such as jogging/running and/or heavy resistance training at least three times per week. * Willing to refrain from taking any products, medications, or supplements that target energy, cognition, or physical performance during the test period. * Anyone with a BMI 18.5 to 30. * Anyone who has access to a device (e.g., smartphone, laptop, computer) for reliable internet. * Anyone who is generally healthy - does not live with any uncontrolled chronic disease. * Anyone willing to maintain a consistent diet and physical activity throughout study duration. Exclusion Criteria: * Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders. * Anyone suffering from gastrointestinal disorders including but not limited to small intestinal bacterial overgrowth (SIBO), irritable bowel syndrome (IBS), and celiac disease. * Anyone suffering from hyperkalemia (high potassium), liver disease, or kidney disease. * Anyone taking ACE inhibitors or potassium-sparing diuretics, examples include: Spironolactone (Aldactone), Eplerenone (Inspra), Amiloride (Midamor), Triamterene (Maxzide), Lisinopril (Zestril, Prinivil), Enalapril (Vasotec), Ramipril (Altace), Benazepril (Lotensin), Quinapril (Accupril), Losartan (Cozaar), Valsartan (Diovan), Olmesartan (Benicar), Irbesartan (Avapro), Lithium carbonate (Lithobid, Eskalith). * Anyone taking antibiotics. * Anyone with any allergies or sensitivities to any of the study product ingredients. * Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period). * Anyone unwilling to follow the study protocol. * Anyone with a history of substance abuse. * Anyone who is a shift worker with an irregular sleep-wake cycle. * Anyone who drinks heavily (8 or more alcoholic drinks per week for women or 15 or more alcoholic drinks per week for men). * Anyone who is currently a smoker or has been a smoker in the past 3 months. * Currently partaking in another research study, or planning to at any point during this study's duration.